Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies.
Open accessThe DOI matches its Crossref record; 656 of the 674 references it cites were found in a registry or an index; 285 of the 444 sources its claims cite were checked for support.
Abstract
Available drugs primarily offer symptomatic relief, while newer anti-amyloid therapies may have disease-modifying effects but still require long-term efficacy and safety validation.
Overview
CoChat Summary
TL;DR
This review synthesizes recent mechanistic, biomarker, clinical-trial, and drug-development advances in Alzheimer’s disease (AD), emphasizing that AD remains multifactorial and that no single hypothesis fully explains its progression. It highlights new FDA-approved disease-modifying antibodies and emerging drug-design strategies such as selective inhibitors, dual-target inhibitors, allosteric modulators, covalent inhibitors, PROTACs, and PPI modulators.
Key findings
- AD is described as a complex disease involving multiple overlapping hypotheses and pathways, including cholinergic, amyloid, tau, neuroinflammation, oxidative stress, metal dyshomeostasis, glutamatergic excitotoxicity, microbiota-gut-brain axis, and abnormal autophagy.
- The review states that recent FDA approvals of aducanumab and lecanemab suggest potential disease-modifying effects, but their long-term efficacy and safety still need further validation.
- For biomarker-based diagnosis, the paper reports that amyloid PET has 90% sensitivity and specificity for diagnosing AD, and that P-tau181 is the most accurate CSF indicator for distinguishing AD from non-AD dementia.
- Traditional symptomatic drugs remain limited: AChE inhibitors and memantine can improve symptoms, but they cannot alter disease course; the paper also notes the donepezil transdermal patch (Adlarity) was FDA-approved in 2022 and showed fewer gastrointestinal adverse events than oral administration.
Methods
- This is a narrative review of recent literature on AD mechanisms, biomarkers, clinical trials, and drug-development strategies.
- The paper synthesizes prior findings across mechanistic hypotheses, biomarker studies, clinical-trial reports, and preclinical/early-stage drug examples rather than presenting a new dataset.
- Its analysis is primarily descriptive and integrative, organizing the field by disease mechanism, diagnostic approach, and therapeutic modality.
Limitations
- The paper states that no unified theory explains AD and that the interplay among pathological aspects requires further elucidation and validation.
- It notes that the high failure rate of clinical trials limits validation of hypotheses and that the long-term efficacy and safety of newer drugs such as aducanumab and lecanemab still need further study.
- Evident from the text: much of the drug-development discussion is based on preclinical studies, animal models, or early-phase trials, so many proposed strategies remain unconfirmed in larger human studies.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
187 Valid · 4 Not valid · 68 Not checked · 29 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However, recent approvals of aducanumab (1) and lecanemab (2) by the Food and Drug Administration (FDA) present the potential in disrease-modifying effects.”
§ Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies > Abstract
What the sources say
- Not matchedcites [1] WHO. A blueprint for dementia research. Geneva: World Health Organization (2022).
Its entry has no title and year that we can search by.
- Disputedcites [2] Knopman, D. S. et al. Alzheimer disease. Nat. Rev. Dis. Prim. 7, 33 (2021). 33986301 10.1038/s41572-021-00269-y PMC8574196 sourceExperimental — accuracy not yet measured
The paper describes aducanumab as being considered by the FDA, not approved, and lecanemab as being in late-stage trials. It discusses possible clinical benefit from anti-amyloid therapies but says their future role remains uncertain. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Proteomic studies found elevated C1q levels in MCI and AD groups, and increased CatB concentration in CSF Aβ42-positive cases.”
§ Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies > Clinical trials of AD > Biomarkers for AD diagnosis
What the sources say
- Partly supportedcites [383] Yuyama, K. et al. Extracellular vesicle proteome unveils cathepsin B connection to Alzheimer’s disease pathogenesis. Brain 147, 627–636 (2023). 10.1093/brain/awad361 PMC10834236 38071653 sourceExperimental — accuracy not yet measured
The section “Elevated CatB levels in CSF and plasma extracellular vesicles during amyloid pathogenesis” reports significantly higher CSF extracellular-vesicle CatB in amyloid-positive than amyloid-negative groups. The claim omits the extracellular-vesicle qualifier; the reported increase is not established for CatB in CSF generally. Page numbers are not provided in our copy. (LLM, conf=0.85)
- Disputedcites [384] Chatterjee, M. et al. C1q is increased in cerebrospinal fluid‐derived extracellular vesicles in Alzheimer’s disease: A multi‐cohort proteomics and immuno‐assay validation study. Alzheimers Dement. 19, 4828–4840 (2023). 37023079 10.1002/alz.13066 sourceExperimental — accuracy not yet measured
Section 3.2.3 (page unavailable) reports that cathepsin B (CTSB) was significantly decreased in CSF-derived extracellular vesicles from AD patients compared with controls. It also reports no difference in CTSB levels in neat CSF between those groups, not an increase. The passage does not report a separate result for Aβ42-positive cases. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“New drugs, including sodium oligomannate (9, GV-971),54–56 aducanumab (1),57–59 lecanemab (2),60–62 and donanemab (10, currently under review for market approval),63 which aim to offer disease-modifying therapies that intervene in the progression of AD.”
§ Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies > Introduction
What the sources say
- Not checked — no full text of the sourcecites [54] Syed, Y. Y. Sodium Oligomannate: First Approval. Drugs 80, 441–444 (2020). 32020555 10.1007/s40265-020-01268-1 source
- Supportedcites [55] Wang, T. et al. A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia. Alzheimers Res. Ther. 12, 110 (2020). 32928279 10.1186/s13195-020-00678-3 PMC7489025 source
The citation attached to this paper concerns sodium oligomannate (GV-971), not the other named drugs. The Background contrasts drugs that do not slow AD pathology with disease-modifying approaches, and the Discussion describes GV-971 acting on Aβ aggregation and neuroinflammation. This supports the claim that it aims to intervene in disease progression; the claim does not say that it has been proven to do so. (LLM, conf=0.85)
- Supportedcites [56] Xiao, S. et al. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia. Alzheimers Res. Ther. 13, 62 (2021). 33731209 10.1186/s13195-021-00795-7 PMC7967962 source
The citation to this paper is attached to sodium oligomannate (GV-971), not the other drugs in the sentence. The Discussion says GV-971’s proposed effects on AD pathology may delay disease progression, while noting that its mechanism requires further investigation; this supports the claim that it aims to intervene in progression, rather than establishing that it does so. (LLM, conf=0.90)
- Supportedcites [57] Cummings, J. & Salloway, S. Aducanumab: Appropriate use recommendations. Alzheimers Dement 18, 531–533 (2022). 34314093 10.1002/alz.12444 PMC8792094 source
The citation attached to this source follows “aducanumab,” so the other named drugs are not attributed to it. The Additional information section describes aducanumab as addressing the underlying pathophysiology of AD, and the Abstract describes its expected outcome as slowing decline, while noting uncertainty about clinical benefit. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [58] Dhillon, S. Aducanumab: First Approval. Drugs 81, 1437–1443 (2021). 34324167 10.1007/s40265-021-01569-z source
- Supportedcites [59] Behl, T. et al. “Aducanumab” making a comeback in Alzheimer’s disease: An old wine in a new bottle. Biomed. Pharmacother.148, 112746 (2022). 35231697 source
The citation is attached to aducanumab, not to the other drugs listed. Section 2 calls aducanumab a disease-modifying agent for Alzheimer’s disease and distinguishes it from treatments that do not change or retard disease progression. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [60] Larkin, H. D. Lecanemab Gains FDA Approval for Early Alzheimer Disease. JAMA 329, 363 (2023). 36652625 10.1001/jama.2022.24494 source
- Not checked — no full text of the sourcecites [61] Harris, E. Alzheimer Drug Lecanemab Gains Traditional FDA Approval. JAMA 330, 495 (2023). 37466999 source
- Supportedcites [62] van Dyck, C. H. et al. Lecanemab in early Alzheimer’s disease. N. Engl. J. Med. 388, 9–21 (2023). 36449413 10.1056/NEJMoa2212948 source
The citation to this paper is attached to lecanemab, not the other drugs in the list. The introduction (p. 10) describes lecanemab as an anti-amyloid antibody being tested for early Alzheimer’s disease, and the conclusion (p. 16) reports moderately less clinical decline than with placebo. This supports describing it as aiming to modify disease progression, without claiming that long-term efficacy is established. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“The accumulation of Aβ is a hallmark pathological feature in both extensively studied autosomal dominant AD and sporadic late-onset AD patients.110”
§ Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies > Mechanisms of AD > Amyloid hypothesis
What the sources say
- Supportedcites [110] Morris, J. C. et al. Autosomal dominant and sporadic late onset Alzheimer’s disease share a common in vivo pathophysiology. Brain 145, 3594–3607 (2022). 35580594 10.1093/brain/awac181 PMC9989348 source
The Introduction identifies cerebral Aβ accumulation as a molecular biomarker of Alzheimer’s disease and compares it in autosomal dominant AD and sporadic late-onset AD. The Abstract reports amyloid accumulation in both groups, though it was greater after symptomatic onset in the autosomal dominant group. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Nonetheless, pathological changes in the brain begin during the preclinical stage, decades before clinical symptoms.”
§ Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies > Introduction
What the sources say
- Supportedcites [4] 2023 Alzheimer’s disease facts and figures. Alzheimers Dement. 19, 1598–1695 (2023). 36918389 source
Section 2.4.1 describes brain changes in the preclinical phase before symptoms develop. Section 2.9 states that Alzheimer's disease begins 20 years or more before symptom onset, supporting the claimed timescale. (LLM, conf=0.92)
- Supportedcites [20] Lloret, A. et al. When does Alzheimer’s disease really start? The role of biomarkers. Int J. Mol. Sci. 20, 5536 (2019). 31698826 10.3390/ijms20225536 PMC6888399 source
Section 2 describes a preclinical stage with pathological brain changes and no evident clinical symptoms. Section 4 states that these lesions can begin decades before the earliest symptoms, while a person is still cognitively normal. (LLM, conf=0.94)
- Supportedcites [21] Porsteinsson, A. P. et al. Diagnosis of early Alzheimer’s disease: Clinical practice in 2021. J. Prev. Alzheimers Dis. 8, 371–386 (2021). 34101796 source
The Introduction describes preclinical Alzheimer’s disease as an asymptomatic stage with evidence of pathology and states that amyloid plaques typically appear about 20 years before cognitive impairment. “The importance of an early diagnosis” explicitly says the pathological hallmarks can be detected decades before symptoms. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
123 more claims · 79 with their cited sources checked
Create a free account to see all 288 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 135
- Probably not a substantial claim. 31
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tau hyperphosphorylation disrupts microtubule stability, promotes intraneuronal aggregates, synaptic dysfunction, and neuronal loss [5,6].”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Aβ aggregation into oligomers, fibrils, and senile plaques initiates a neurotoxic cascade, including tau hyperphosphorylation, mitochondrial dysfunction, and neuroinflammation [5].”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“During this phase, NPs designed to target Aβ plaques—a key feature of AD—as well as anti-inflammatory pathways, have shown higher bioavailability and effectiveness [80, 144].”
From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [80]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The pathophysiological process of AD is multifaceted, involving several key hypotheses: the cholinergic, glutamatergic, amyloid, tau protein, inflammatory, microbiota–gut–brain axis, oxidative stress, metal ion, and abnormal autophagy hypotheses, as shown in the summary of AD pathophysiology in Figure 1 [8].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“Dysregulated processing of amyloid precursor protein (APP) generates toxic Aβ species, triggering oxidative stress, mitochondrial dysfunction, calcium dysregulation, and neuroinflammation [5].”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [5]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Items 401–600 of 656
Repurposed agents in the Alzheimer’s disease drug development pipeline
Bauzon, J., Lee, G., & Cummings, J. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00662-x · Cited by 77
Li, Y., Sang, S., Ren, W., Pei, Y., Bian, Y., Chen, Y., & Sun, H. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113874 · Cited by 77 · cited 1×
“504,505 Among them, HDAC6 has two catalytic domains and a C-terminal zinc fi nger domain, interacts with tau and α -tubulin, and is involved in the degradation of protein aggregates, mitochondrial transport, and cognitive memory, 506 – 509 making it relevant to AD pathology.”
BackgroundThe Omnipresence of DYRK1A in Human Diseases
Deboever, E., Fistrovich, A., Hulme, C., & Dunckley, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169355 · Cited by 77 · cited 1×
“…relevant substrates such as tau, APP, PS1, regulation of axonal transport of APP, and participation in the selective splicing of tau pre-mRNA, 500 – 502 the compound dp-FINDY ( 37 ) effectively targets the spatial dynamic changes in the ATP-binding site between the DYRK1A folding intermediate and…”
BackgroundTargeting autophagy in Alzheimer’s disease: Animal models and mechanisms
Zhang, X.-W., 澳门大学中华医药研究院中药质量研究国家重点实验室, 澳. 凼. 9., State Key Laboratory of Quality Research in Chinese Medicine, I. O. C. M. S., Zhu, X.-X., Tang, D.-S., Lu, J.-H., 佛山大学广东省动物分子设计与精准育种重点实验室, 广., & Guangdong Provincial Key Laboratory of Animal Molecular Design and Precise Breeding, G. E. T. C. O. G. P. (2023) · Zoological Research · doi:10.24272/j.issn.2095-8137.2023.294 · Cited by 77 · cited 3×
“220,221 It primarily occurs via three types: micro-autophagy, chaperone-mediated autophagy, and macroauto-phagy (commonly referred to as autophagy).”
BackgroundThe role of amyloid $beta;-protein in Alzheimer's disease
Regland, B., & Gottfries, C. G. (1992) · The Lancet · doi:10.1016/0140-6736(92)91780-c · Cited by 76
Lista, S., Garaci, F. G., Ewers, M., Teipel, S., Zetterberg, H., Blennow, K., & Hampel, H. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.04.506 · Cited by 76
Preclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention
Rynearson, K. D., Ponnusamy, M., Prikhodko, O., Xie, Y., Zhang, C., Nguyen, P., Hug, B., Sawa, M., Becker, A., Spencer, B., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20202560 · Cited by 76
Cao, Q., Shin, W. S., Chan, H., Vuong, C. K., Dubois, B., Li, B., Murray, K. A., Sawaya, M. R., Feigon, J., Black, D. L., et al. (2018) · Nature Chemistry · doi:10.1038/s41557-018-0147-z · Cited by 75 · cited 1×
“585 Compounds ALI6 ( 65 ) 586 and 66 587 can effectively block this interaction, which reverses the changes in co fi lin signaling downstream of LilrB2 and the inhibition of neurite outgrowth, thus protecting neuronal cells from A β toxicity.”
BackgroundLow-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial
Schneider, L. S., Geffen, Y., Rabinowitz, J., Thomas, R. G., Schmidt, R., Ropele, S., Weinstock, M., & on behalf of the Ladostigil Study Group (2019) · Neurology · doi:10.1212/wnl.0000000000008239 · Cited by 75
Tsuji, S., Hase, T., Yachie-Kinoshita, A., Nishino, T., Ghosh, S., Kikuchi, M., Shimokawa, K., Aburatani, H., Kitano, H., & Tanaka, H. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00826-3 · Cited by 75
The potential clinical value of plasma biomarkers in Alzheimer's disease
Blennow, K., Galasko, D., Perneczky, R., Quevenco, F., van der Flier, W. M., Akinwonmi, A., Carboni, M., Jethwa, A., Suridjan, I., & Zetterberg, H. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13455 · Cited by 75
Calcium signalling and ER stress in insulin resistance and atherosclerosis
Özcan, L., & Tabas, I. A. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12562 · Cited by 74 · cited 1×
“315 – 318 In AD, enhanced activity of L-type VGCCs, potentially related to their interaction with A β /tau, promotes excessive calcium in fl ux into cells.”
BackgroundGeoffroy, C., Paoletti, P., & Mony, L. (2022) · The Journal of Physiology · doi:10.1113/jp280875 · Cited by 74
α7 nicotinic acetylcholine receptors in the hippocampal circuit: taming complexity
Letsinger, A. C., Gu, Z., & Yakel, J. L. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2021.11.006 · Cited by 74
Triaca, V., Sposato, V., Bolasco, G., Ciotti, M. T., Pelicci, P., Bruni, A. C., Cupidi, C., Maletta, R., Feligioni, M., Nisticò, R., et al. (2016) · Aging Cell · doi:10.1111/acel.12473 · Cited by 73 · cited 1×
“345 The accumulation of proNGF and downregulation of TrkA (pro-survival signal) levels favor the predominance of pro-apoptotic signaling mediated by p75 NTR , further promoting the degeneration of basal forebrain cholinergic neurons.”
BackgroundCryptic pocket formation underlies allosteric modulator selectivity at muscarinic GPCRs
Hollingsworth, S. A., Kelly, B., Valant, C., Michaelis, J. A., Mastromihalis, O., Thompson, G., Venkatakrishnan, A. J., Hertig, S., Scammells, P. J., Sexton, P. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11062-7 · Cited by 73 · cited 1×
“548 Compared to orthosteric sites, allosteric sites often have lower conservation and greater diversity, 549 providing new avenues for drug development targeting highly homologous subtypes, such as nAChR and mAChR.”
BackgroundSun, Y., Huang, J., Chen, Y., Shang, H., Zhang, W., Yu, J., He, L., Xing, C., & Zhuang, C. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104172 · Cited by 73
Ca2+ Dyshomeostasis Disrupts Neuronal and Synaptic Function in Alzheimer’s Disease
McDaid, J., Mustaly-Kalimi, S., & Stutzmann, G. E. (2020) · Cells · doi:10.3390/cells9122655 · Cited by 73
Liu, S., Hossinger, A., Heumüller, S.-E., Hornberger, A., Buravlova, O., Konstantoulea, K., Müller, S. A., Paulsen, L., Rousseau, F., Schymkowitz, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25855-2 · Cited by 72
Huang, S., Zhang, Z., Cao, J., Yu, Y., & Pei, G. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01006-x · Cited by 72 · cited 1×
“279 Litvinchuk et al. revealed a potential synergistic effect between APOE4 and tau pathology, wherein APOE4 may induce the abnormal accumulation of certain cholesterol esters in glial cells.”
BackgroundLee, H.-Y., Fan, S.-J., Huang, F.-I., Chao, H.-Y., Hsu, K.-C., Lin, T. E., Yeh, T.-K., Lai, M.-J., Li, Y.-H., Huang, H.-L., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00151 · Cited by 71 · cited 1×
“514 In most cases of selective inhibitor development, research initially relies on the scaffold of lead compounds to provide basic af fi nity and molecular framework.”
MethodSmall molecules targeting protein–protein interactions for cancer therapy
Wu, D., Li, Y., Zheng, L., Xiao, H., Ouyang, L., Wang, G., & Sun, Q. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.035 · Cited by 71 · cited 1×
“75,579 582 Thus, disrupting these interactions may block some critical signaling pathways and potentially mitigate the pathological process of AD.”
BackgroundWang, W., Li, Y., Ma, F., Sheng, X., Chen, K., Zhuo, R., Wang, C., Zheng, H., Zhang, Y.-W., Bu, G., et al. (2023) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2023.07.011 · Cited by 71
Self-citationDevelopment of covalent inhibitors: Principle, design, and application in cancer
Zheng, L., Li, Y., Wu, D., Xiao, H., Zheng, S., Wang, G., & Sun, Q. (2023) · MedComm – Oncology · doi:10.1002/mog2.56 · Cited by 71 · cited 1×
“565,567,573”
Mitochondria-associated membranes: A hub for neurodegenerative diseases
Liu, J., & Yang, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112890 · Cited by 71 · cited 1×
“324 – 326 Under the in fl uence of A β , the expression of some MAM-related proteins, such as IP3Rs and VDAC1, is signi fi cantly increased, 325,327,328 leading to mitochondrial Ca 2 + overload, inhibition of normal ATP synthesis, and potential release of apoptotic signals.”
BackgroundDonepezil, a drug for Alzheimer’s disease, promotes oligodendrocyte generation and remyelination
Cui, X. J., Guo, Y., Fang, J., Shi, C., Suo, N., Zhang, R., & Xie, X. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0206-4 · Cited by 70 · cited 1×
“516 Hah et al. have conducted in-depth studies on this target, continuously re fi ning and developing several generations of compounds based on the structure of pan-JNK inhibitor 42 , which was identi fi ed through an in-house kinase-focused library screening.”
BackgroundA mechanistic survey of Alzheimer's disease
Tang, Y., Zhang, D., Gong, X., & Zheng, J. (2021) · Biophysical Chemistry · doi:10.1016/j.bpc.2021.106735 · Cited by 70 · cited 1×
“150,155 Under pathological conditions, an imbalanced activity of phosphatases and kinases leads to hyperphosphorylation of tau.”
BackgroundBosch, M. E., Dodiya, H. B., Michalkiewicz, J., Lee, C., Shaik, S. M., Weigle, I. Q., Zhang, C., Osborn, J., Nambiar, A., Patel, P., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00700-w · Cited by 70
Memantine ER/Donepezil: A Review in Alzheimer’s Disease
Greig, S. L. (2015) · CNS Drugs · doi:10.1007/s40263-015-0287-2 · Cited by 69
Ciccone, L., Shi, C., di Lorenzo, D., Van Baelen, A.-C., & Tonali, N. (2020) · Molecules · doi:10.3390/molecules25102439 · Cited by 69
Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer’s disease
Zhao, A., Jiao, Y., Ye, G., Kang, W., Tan, L., Li, Y., Deng, Y., & Liu, J. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158708 · Cited by 69
High-throughput target trial emulation for Alzheimer’s disease drug repurposing with real-world data
Zang, C., Zhang, H., Xu, J., Zhang, H., Fouladvand, S., Havaldar, S., Cheng, F., Chen, K., Chen, Y., Glicksberg, B. S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43929-1 · Cited by 69
Pentz, R., Iulita, M. F., Ducatenzeiler, A., Bennett, D. A., & Cuello, A. C. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0797-2 · Cited by 68 · cited 1×
“15 In AD, there is a reduction in the conversion of proNGF to mature NGF and an enhancement in the degradation of mature NGF, 344 leading to a de fi ciency in mature NGF and accumulation of proNGF in the brain.”
BackgroundMorris, J. C., Weiner, M., Xiong, C., Beckett, L., Coble, D., Saito, N., Aisen, P. S., Allegri, R., Benzinger, T. L. S., Berman, S. B., et al. (2022) · Brain · doi:10.1093/brain/awac181 · Cited by 68
Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs
Nunes, D., Loureiro, J. A., & Pereira, M. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112296 · Cited by 68
Iranpour, M., Moghadam, A. R., Yazdi, M., Ande, S. R., Alizadeh, J., Wiechec, E., Lindsay, R., Drebot, M., Coombs, K. M., & Ghavami, S. (2016) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2015.19 · Cited by 67
Xiang, J., Wang, Z.-H., Ahn, E. H., Liu, X., Yu, S.-P., Manfredsson, F. P., Sandoval, I. M., Ju, G., Wu, S., & Ye, K. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901348116 · Cited by 67
A Neurotoxic Ménage-à-trois: Glutamate, Calcium, and Zinc in the Excitotoxic Cascade
Granzotto, A., Canzoniero, L. M. T., & Sensi, S. L. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.600089 · Cited by 67 · cited 1×
“210,211 Overall, pharmaceutical validation of the glutamatergic excitotoxicity hypothesis demonstrates the effectiveness of neurotransmitter regulation in improving cognitive symptoms.”
BackgroundAPOE interacts with ACE2 inhibiting SARS-CoV-2 cellular entry and inflammation in COVID-19 patients
Zhang, H., Shao, L., Lin, Z., Long, Q.-X., Yuan, H., Cai, L., Jiang, G., Guo, X., Yang, R., Zhang, Z., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01118-4 · Cited by 67
Self-citationLAWLOR, B. A., & Davis, K. L. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90227-q · Cited by 66
Novel targets in Alzheimer’s disease: A special focus on microglia
Balducci, C., & Forloni, G. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.017 · Cited by 66 · cited 1×
“172 ,173 A β is a typical trigger for microglial activation.”
BackgroundHe, F., Chou, C. J., Scheiner, M., Poeta, E., Yuan Chen, N., Gunesch, S., Hoffmann, M., Sotriffer, C., Monti, B., Maurice, T., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01940 · Cited by 66 · cited 1×
“513 Compound 39 achieved strong HDAC6 selectivity through interaction with another speci fi c pocket on HDAC6, inhibiting tau hyperphosphorylation and aggregation.”
BackgroundImmunotherapies for Alzheimer’s disease
Golde, T. E., & Levey, A. I. (2023) · Science · doi:10.1126/science.adj9255 · Cited by 66
Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property
Liu, K., Liu, Y., Li, L., Qin, P., Iqbal, J., Deng, Y., & Qing, H. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.12.002 · Cited by 65 · cited 1×
“158 – 160 Additionally, other post-translational modi fi cations, including truncation, 161,162 glycosylation, 163 glycation, 164 and sumoylation, 165 play an active role in promoting tau aggregation and increasing its toxicity.”
BackgroundPedriali, G., Rimessi, A., Sbano, L., Giorgi, C., Wieckowski, M. R., Previati, M., & Pinton, P. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00180 · Cited by 65
Aducanumab: Appropriate use recommendations
Cummings, J., & Salloway, S. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12444 · Cited by 65
Feng, L., Wang, G., Chen, Y., He, G., Liu, B., Liu, J., Chiang, C., & Ouyang, L. (2022) · Medicinal Research Reviews · doi:10.1002/med.21859 · Cited by 65 · cited 3×
“588 Iododi fl unisal ( 67 , IDIF), luteolin ( 68 ), and three marketed drugs sulindac ( 69 ), olsalazine ( 70 ), and fl ufenamic ( 71 ) are small-molecule chaperones for the TTR/A β interaction.”
BackgroundDefective mitophagy and the etiopathogenesis of Alzheimer’s disease
Zeng, K., Yu, X., Mahaman, Y. A. R., Wang, J., Liu, R., Li, Y., & Wang, X. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00305-1 · Cited by 65 · cited 1×
“305 PINK1/parkin cascades related to A β , APP-CTFs, tau, and the APOE4 isoform could lead to the accumulation of damaged mitochondria.”
BackgroundSelf-citationA review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
Maciejewska, K., Czarnecka, K., & Szymański, P. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00293-5 · Cited by 64 · cited 1×
“Currently, antibodies like aducanumab ( 1 ), lecanemab ( 2 ), and donanemab ( 10 ) show their promise in proving A β as a signi fi cant factor in AD development.”
BackgroundTacrines for Alzheimer's disease therapy. III. The PyridoTacrines
de los Ríos, C., & Marco-Contelles, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.005 · Cited by 63 · cited 2×
“Compounds 40 and 41 were identi fi ed through a combination of docking-based virtual screening and pharmacophore modeling from an in-house oncology compound library.”
BackgroundMethodChandra, S., & Pahan, K. (2019) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-190104 · Cited by 63
Fine Tuning Muscarinic Acetylcholine Receptor Signaling Through Allostery and Bias
van der Westhuizen, E. T., Choy, K. H. C., Valant, C., McKenzie-Nickson, S., Bradley, S. J., Tobin, A. B., Sexton, P. M., & Christopoulos, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.606656 · Cited by 63 · cited 1×
“545 This precise tuning of receptor activity has revitalized the development of anti-γ -secretase drugs in the fi eld of AD.”
BackgroundHajjo, R., Sabbah, D. A., Abusara, O. H., & Bawab, A. Q. A. (2022) · Diagnostics · doi:10.3390/diagnostics12122975 · Cited by 63 · cited 2×
“585 Compounds ALI6 ( 65 ) 586 and 66 587 can effectively block this interaction, which reverses the changes in co fi lin signaling downstream of LilrB2 and the inhibition of neurite outgrowth, thus protecting neuronal cells from A β toxicity.”
BackgroundCheng, F., Wang, F., Tang, J., Zhou, Y., Fu, Z., Zhang, P., Haines, J. L., Leverenz, J. B., Gan, L., Hu, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101379 · Cited by 63
Advances in RIPK1 kinase inhibitors
Chen, L., Zhang, X., Ou, Y., Liu, M., Yu, D., Song, Z., Niu, L., Zhang, L., & Shi, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.976435 · Cited by 63
Self-citationStructure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
Luo, Y., & Li, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228828 · Cited by 62
Amyloid-β: A double agent in Alzheimer's disease?
Yu, H., & Wu, J. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111575 · Cited by 62
Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development
Chen, J., Tang, P., Wang, Y., Wang, J., Yang, C., Li, Y., Yang, G., Wu, F., Zhang, J., & Ouyang, L. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01835 · Cited by 62 · cited 1×
“588 Iododi fl unisal ( 67 , IDIF), luteolin ( 68 ), and three marketed drugs sulindac ( 69 ), olsalazine ( 70 ), and fl ufenamic ( 71 ) are small-molecule chaperones for the TTR/A β interaction.”
BackgroundSelf-citationA novel lysosome‐to‐mitochondria signaling pathway disrupted by amyloid‐β oligomers
Norambuena, A., Wallrabe, H., Cao, R., Wang, D. B., Silva, A., Svindrych, Z., Periasamy, A., Hu, S., Tanzi, R. E., Kim, D. Y., et al. (2018) · The EMBO Journal · doi:10.15252/embj.2018100241 · Cited by 61 · cited 1×
“…oligomers are the primary neurotoxic substances, 131 – 133 disruption of cell membrane integrity, 134 activation in in fl ammatory responses, 135,136 causes of calcium homeostasis imbalance 137 and mitochondrial dysfunction, 138 – 140 triggers in oxidative stress, 141 and damage factor of synapses.”
BackgroundQu, L., Li, S., Ji, L., Luo, S., Ding, M., Yin, F., Wang, C., Luo, H., Lu, D., Liu, X., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113889 · Cited by 61 · cited 1×
“576 Additionally, phosTAC7 ( 63 ) 577 and tau2-8 ( 64 ) 578 ingeniously leverage the fl exibility of PROTACs to create targeted dephosphorylation strategies.”
BackgroundZetterberg, H. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12618 · Cited by 61
Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease
Dwomoh, L., Tejeda, G. S., & Tobin, A. B. (2022) · Neuronal Signaling · doi:10.1042/ns20210004 · Cited by 60
Georgieva, D., Nikolova, D., Vassileva, E., & Kostova, B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030829 · Cited by 60
Zou, D., Liu, R., Lv, Y., Guo, J., Zhang, C., & Xie, Y. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2270781 · Cited by 60 · cited 1×
“524,525 From a biochemical standpoint, growing evidence supports a link between cholinergic abnormalities and other pathophysiological features of AD, including abnormal A β and tau.”
BackgroundPathogenesis of sporadic Alzheimer's disease by deficiency of NMDA receptor subunit GluN3A
Zhong, W., Wu, A., Berglund, K., Gu, X., Jiang, M. Q., Talati, J., Zhao, J., Wei, L., & Yu, S. P. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12398 · Cited by 59
Turning the tide on Alzheimer’s disease: modulation of γ-secretase
Luo, J. E., & Li, Y.-M. (2022) · Cell & Bioscience · doi:10.1186/s13578-021-00738-7 · Cited by 59
Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications
Taléns-Visconti, R., de Julián-Ortiz, J. V., Vila-Busó, O., Diez-Sales, O., & Nácher, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051399 · Cited by 59 · cited 1×
“401,406,407 Furthermore, the combination use of appropriate cholinesterase inhibitors, such as donepezil ( 4 ) and galantamine ( 6 ), or the combination of cholinesterase inhibitors with other neurologic drugs, metal chelators, or antioxidants, may yield surprising effects in the management of…”
BackgroundPharmacological modulation of autophagy for Alzheimer's disease therapy: Opportunities and obstacles
Deng, Z., Dong, Y., Zhou, X., Lu, J.-H., & Yue, Z. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.009 · Cited by 58 · cited 2×
“227,229 In AD, autophagy defects mediate the disruption of protein homeostasis networks (production and extracellular secretion of A β , abnormal aggregation of tau protein) and lead to the accumulation of damaged organelles, such as dysfunctional mitochondria.”
BackgroundKim, M., Lee, J.-H., Jung, K., Kim, M., Park, Y.-J., Ahn, H., Kwon, Y. H., & Hah, J. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.02.021 · Cited by 57
Molecular mechanisms of mitophagy and its roles in neurodegenerative diseases
Li, X., Huang, L., Lan, J., Feng, X., Li, P., Wu, L., & Peng, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105240 · Cited by 57 · cited 2×
“304 Calcium signaling Intracellular calcium could originate from the opening of plasma membrane calcium channels, such as voltage-gated and ligand-gated calcium channels, and the release of organelles like the ER and mitochondria.”
BackgroundOnce upon a time, the Amyloid Cascade Hypothesis
Granzotto, A., & Sensi, S. L. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102161 · Cited by 57
Sticking it to KRAS: Covalent Inhibitors Enter the Clinic
McCormick, F. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.009 · Cited by 56
Overview of therapeutic targets in management of dementia
Malik, R., Kalra, S., Bhatia, S., Al‐Harrasi, A., Singh, G., Mohan, S., Makeen, H. A., Albratty, M., Meraya, A. M., Bahar, B., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113168 · Cited by 56
Ahmed, H., Wang, Y., Griffiths, W. J., Levey, A. I., Pikuleva, I., Liang, S. H., & Haider, A. (2024) · Brain · doi:10.1093/brain/awae028 · Cited by 56 · cited 1×
“273 – 275 In AD, cholesterol biosynthesis and catabolism are impaired, contributing to the progression of AD through mediation of A β , tau, in fl ammation, and other pathological changes.”
BackgroundThe Failure of Solanezumab — How the FDA Saved Taxpayers Billions
Sacks, C. A., Avorn, J., & Kesselheim, A. S. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1701047 · Cited by 55
Alzheimer disease and the periodontal patient: New insights, connections, and therapies
Ryder, M. I., & Xenoudi, P. (2021) · Periodontology 2000 · doi:10.1111/prd.12389 · Cited by 55 · cited 1×
“594,595 598 Research of both HSV1-infected mice and AD mouse models has revealed the gene MAM domain containing 2 (MAMDC2) exhibits signi fi cant expression in microglia, which results in high levels of I-IFNs to enhance antiviral responses in HSV1-infected mice and neuroin fl ammation in the AD…”
BackgroundMustaly-Kalimi, S., Gallegos, W., Marr, R. A., Gilman-Sachs, A., Peterson, D. A., Sekler, I., & Stutzmann, G. E. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211999119 · Cited by 55 · cited 1×
“330 Insulin signaling Insulin regulates glucose metabolism, neuronal growth and survival, synaptic plasticity, and cognition, 331 – 333 functions closely linked to two main insulin signaling pathways: phosphatidylinositol 3-kinase (PI3K)-Akt and Ras/Raf-MAPK.”
BackgroundDrug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review
Grabowska, M. E., Huang, A., Wen, Z., Li, B., & Wei, W.-Q. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1257700 · Cited by 55
Wischik, C. M., Bentham, P., Gauthier, S., Miller, S., Kook, K., & Schelter, B. O. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2022.63 · Cited by 55
Liang, Z., & Li, Q. X. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00010 · Cited by 54
LILRB2-mediated TREM2 signaling inhibition suppresses microglia functions
Zhao, P., Xu, Y., Jiang, L.-L., Fan, X., Ku, Z., Li, L., Liu, X., Deng, M., Arase, H., Zhu, J.-J., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00550-y · Cited by 54
Sun, Y., Xu, L., Zheng, D., Wang, J., Liu, G., Mo, Z., Liu, C., Zhang, W., Yu, J., Xing, C., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102793 · Cited by 54
Self-citationLi, Z., Yin, B., Zhang, S., Lan, Z., & Zhang, L. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115817 · Cited by 54
The role of glial autophagy in Alzheimer’s disease
Litwiniuk, A., Juszczak, G. R., Stankiewicz, A. M., & Urbańska, K. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02242-5 · Cited by 54 · cited 1×
“There is a growing emphasis on the involvement of chaperone-mediated autophagy, 232 contributions of glial cell autophagy, 233,234 and the precise causes of mitochondrial autophagy disorders.”
BackgroundMolecular Targets in Alzheimer’s Disease
Bjørklund, G., Aaseth, J., Dadar, M., & Chirumbolo, S. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1563-9 · Cited by 53
From beta amyloid to altered proteostasis in Alzheimer’s disease
Bruni, A. C., Bernardi, L., & Gabelli, C. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101126 · Cited by 53 · cited 1×
“77,148 149 – 151 Tau protein hypothesis As a major component of NFTs, tau protein exhibits a spatial and temporal distribution that strongly correlates with clinical symptoms, making it a highly speci fi c pathological biomarker in AD patients.”
BackgroundMakhaeva, G. F., Kovaleva, N. V., Boltneva, N. P., Lushchekina, S. V., Astakhova, T. Y., Rudakova, E. V., Proshin, A. N., Serkov, I. V., Radchenko, E. V., Palyulin, V. A., et al. (2020) · Molecules · doi:10.3390/molecules25173915 · Cited by 53
Wandering beyond small molecules: peptides as allosteric protein modulators
Mannes, M., Martin, C., Menet, C. J., & Ballet, S. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.10.011 · Cited by 53
Morató, X., Pytel, V., Jofresa, S., Ruiz, A., & Boada, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169305 · Cited by 53
Zheng, Y., Zhang, X., Zhang, R., Wang, Z., Gan, J., Gao, Q., Yang, L., Xu, P., & Jiang, X. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5314 · Cited by 52
The Autophagy-Lysosomal Pathways and Their Emerging Roles in Modulating Proteostasis in Tumors
Dong, Z., & Cui, H. (2018) · Cells · doi:10.3390/cells8010004 · Cited by 51 · cited 1×
“220,223,224 226 Macroautophagy, the main subtype, is primarily regulated by mTORC1 for activating the unc-51-like autophagy activating kinase 1 (ULK1) complex and dephosphor-ylating transcription factor EB (TFEB) to induce autophagy.”
BackgroundBioactive human Alzheimer brain soluble Aβ: pathophysiology and therapeutic opportunities
Li, S., & Stern, A. M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01589-5 · Cited by 51
Pan- and isoform-specific inhibition of Hsp90: Design strategy and recent advances
Yu, J., Zhang, C., & Song, C. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114516 · Cited by 51
The role of neurotrophic factors in novel, rapid psychiatric treatments
Kim, J., He, M. J., Widmann, A. K., & Lee, F. S. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01717-x · Cited by 51 · cited 1×
“342,343 In AD, key neurotrophic factors include NGF and brain-derived neurotrophic factor (BDNF), which exert their effects through speci fi c receptors such as tropomyosin-related kinase (Trk) and p75 NTR .”
BackgroundModulation of the Aβ peptide aggregation pathway by KP1019 limits Aβ-associated neurotoxicity
Jones, M. R., Mu, C., Wang, M. C. P., Webb, M. I., Walsby, C. J., & Storr, T. (2015) · Metallomics · doi:10.1039/c4mt00252k · Cited by 50 · cited 1×
“568 This suggests that metal-based covalent inhibitors have promising potential in AD drug development.”
Background“Aducanumab” making a comeback in Alzheimer’s disease: An old wine in a new bottle
Behl, T., Kaur, I., Sehgal, A., Singh, S., Sharma, N., Makeen, H. A., Albratty, M., Alhazmi, H. A., Felemban, S. G., Alsubayiel, A. M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112746 · Cited by 50
Webber, E. K., Fivaz, M., Stutzmann, G. E., & Griffioen, G. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13065 · Cited by 50 · cited 2×
“307 – 309 Calcium plays a multifaceted role in regulating gene expression, neurotransmitter release, membrane excitability, and inducing synaptic plasticity.”
BackgroundBernard-Gauthier, V., Mossine, A. V., Knight, A., Patnaik, D., Zhao, W.-N., Cheng, C., Krishnan, H. S., Xuan, L. L., Chindavong, P. S., Reis, S. A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01030 · Cited by 49
Tong, B. C.-K., Wu, A. J., Huang, A. S., Dong, R., Malampati, S., Iyaswamy, A., Krishnamoorthi, S., Sreenivasmurthy, S. G., Zhu, Z., Su, C., et al. (2022) · Autophagy · doi:10.1080/15548627.2021.1945220 · Cited by 49 · cited 1×
“270 Thus, the relationship among PS1 gene mutations or de fi ciencies, lysosomal acidi fi cation, and lysosomal calcium ion dysregulation warrants further investigation.”
BackgroundFronza, M. G., Alves, D. A. C., Praticò, D., & Savegnago, L. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102033 · Cited by 49
Sheng, J., Zhang, S., Wu, L., Kumar, G., Liao, Y., K., P. G., & Fan, H. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1019187 · Cited by 49
Current Advances in Allosteric Modulation of Muscarinic Receptors
Jakubik, J., & El-Fakahany, E. E. (2020) · Biomolecules · doi:10.3390/biom10020325 · Cited by 48
Vijverberg, E. G. B., Axelsen, T., Bihlet, A. R., Henriksen, K., Weber, F., Fuchs, K., Harrison, J., Kühn‐Wache, K., Alexandersen, P., Prins, N. D., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00882-9 · Cited by 48
Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer’s Disease
Rani, S., Dhar, S. B., Khajuria, A., Gupta, D., Jaiswal, P. K., Singla, N., Kaur, M., Singh, G., & Barnwal, R. P. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01330-y · Cited by 48
The propagation mechanisms of extracellular tau in Alzheimer’s disease
Wei, Y., Liu, M., & Wang, D. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10573-y · Cited by 47 · cited 1×
“153,154 It hosts numerous phosphorylation sites across its N-terminal region, C-terminal region, and repeat region, which are regulated by a balance of various kinases and phosphatases to maintain normal neuronal physiological functions.”
BackgroundDendritic/Post-synaptic Tau and Early Pathology of Alzheimer’s Disease
Yin, X., Zhao, C., Qiu, Y., Zhou, Z., Bao, J., & Qian, W. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.671779 · Cited by 47 · cited 1×
“158 – 160 Additionally, other post-translational modi fi cations, including truncation, 161,162 glycosylation, 163 glycation, 164 and sumoylation, 165 play an active role in promoting tau aggregation and increasing its toxicity.”
BackgroundFehsel, K., & Christl, J. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101592 · Cited by 47
Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer’s Disease
Padhi, D., & Govindaraju, T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00335 · Cited by 47
NIH Pilots Telehealth Program for COVID-19
Larkin, H. D. (2023) · JAMA · doi:10.1001/jama.2022.24494 · Cited by 47
Chatterjee, M., Özdemir, S., Kunadt, M., Koel‐Simmelink, M., Boiten, W., Piepkorn, L., Pham, T. V., Chiasserini, D., Piersma, S. R., Knol, J. C., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13066 · Cited by 47
Extracellular vesicle proteome unveils cathepsin B connection to Alzheimer’s disease pathogenesis
Yuyama, K., Sun, H., Fujii, R., Hemmi, I., Ueda, K., & Igeta, Y. (2024) · Brain · doi:10.1093/brain/awad361 · Cited by 47
Comorbidity‐driven multi‐modal subtype analysis in mild cognitive impairment of Alzheimer's disease
Katabathula, S., Davis, P. B., & Xu, R. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12792 · Cited by 47 · cited 1×
“438 – 441 Avagacestat ( 13 , BMS-708163) is an orally administered γ -secretase inhibitor that exhibited greater selectivity for APP-C99 compared to semagacestat ( 12 , LY450139).”
BackgroundAyton, S., & Bush, A. I. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101212 · Cited by 45
Zhao, K., Liu, J., Sun, T., Zeng, L., Cai, Z., Li, Z., & Liu, R. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.02.016 · Cited by 45
Alzheimer Drug Lecanemab Gains Traditional FDA Approval
Harris, E. (2023) · JAMA · doi:10.1001/jama.2023.12548 · Cited by 45
Tau Abnormalities and the Potential Therapy in Alzheimer’s Disease
Almansoub, H. A. M. M., Tang, H. R., Wu, Y., Wang, D., Mahaman, Y. A. R., Wei, N., Almansob, Y. A. M., He, W., & Liu, D. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180868 · Cited by 43 · cited 1×
“158 – 160 Additionally, other post-translational modi fi cations, including truncation, 161,162 glycosylation, 163 glycation, 164 and sumoylation, 165 play an active role in promoting tau aggregation and increasing its toxicity.”
BackgroundAmadoro, G., Latina, V., Corsetti, V., & Calissano, P. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.165584 · Cited by 43 · cited 1×
“158 – 160 Additionally, other post-translational modi fi cations, including truncation, 161,162 glycosylation, 163 glycation, 164 and sumoylation, 165 play an active role in promoting tau aggregation and increasing its toxicity.”
BackgroundRegulation of Ca2+ exchanges and signaling in mitochondria
Carvalho, E. J., Stathopulos, P. B., & Madesh, M. (2020) · Current Opinion in Physiology · doi:10.1016/j.cophys.2020.08.010 · Cited by 43
Novel Targets for Alzheimer's Disease: A View Beyond Amyloid
Ray, W. J., & Buggia-Prevot, V. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-052919-120219 · Cited by 43 · cited 2×
“166,170 Neuroin fl ammation hypothesis Neuroin fl ammation is generally characterized as a chronic in fl ammatory response in the central nervous system (CNS) that fails to resolve on its own.”
BackgroundAnti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer’s Disease
Amat-ur-Rasool, H., Ahmed, M., Hasnain, S., & Carter, W. G. (2021) · Brain Sciences · doi:10.3390/brainsci11020184 · Cited by 43
Ultrasound delivery of a TrkA agonist confers neuroprotection to Alzheimer-associated pathologies
Xhima, K., Markham-Coultes, K., Hahn Kofoed, R., Saragovi, H. U., Hynynen, K., & Aubert, I. (2022) · Brain · doi:10.1093/brain/awab460 · Cited by 43 · cited 1×
“346,347 Downregulation of BDNF expression leads to weakened BDNF signaling in AD.”
BackgroundEndothelial Progenitor Cells and Vascular Alterations in Alzheimer’s Disease
Custodia, A., Ouro, A., Romaus-Sanjurjo, D., Pías-Peleteiro, J. M., de Vries, H. E., Castillo, J., & Sobrino, T. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.811210 · Cited by 43
Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol
Wang, H., Kulas, J. A., Ferris, H. A., & Hansen, S. B. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.18.159632 · Cited by 42
Diagnostic biomarkers in Alzheimer’s disease
Andersen, E., Casteigne, B., Chapman, W. D., Creed, A., Foster, F., Lapins, A., Shatz, R., & Sawyer, R. P. (2021) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2021.100041 · Cited by 42
Wei, J., Wang, J., Zhang, J., Yang, J., Wang, G., & Wang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114301 · Cited by 42
Self-citationFinding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease
Salasova, A., Monti, G., Andersen, O. M., & Nykjaer, A. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00576-2 · Cited by 42 · cited 1×
“15 In AD, there is a reduction in the conversion of proNGF to mature NGF and an enhancement in the degradation of mature NGF, 344 leading to a de fi ciency in mature NGF and accumulation of proNGF in the brain.”
BackgroundAstrocyte subtype-specific approach to Alzheimer's disease treatment
Sarkar, S., & Biswas, S. C. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.104956 · Cited by 41
Therapeutics of Alzheimer’s Disease: Recent Developments
Burns, S., Selman, A., Sehar, U., Rawat, P., Reddy, A. P., & Reddy, P. H. (2022) · Antioxidants · doi:10.3390/antiox11122402 · Cited by 40 · cited 1×
“65,66 Unfortunately, the current offerings fall short of meeting the need to address cognitive.”
BackgroundHu, X.-L., Guo, C., Hou, J.-Q., Feng, J.-H., Zhang, X.-Q., Xiong, F., Ye, W.-C., & Wang, H. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00252 · Cited by 39
Jiang, X., Zhou, J., Wang, Y., Chen, L., Duan, Y., Huang, J., Liu, C., Chen, Y., Liu, W., Sun, H., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112751 · Cited by 39
Self-citationWhen the infectious environment meets the AD brain
Ganz, T., Fainstein, N., & Ben-Hur, T. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00559-3 · Cited by 39
COVID-19 as a Risk Factor for Alzheimer’s Disease
Golzari-Sorkheh, M., Weaver, D. F., & Reed, M. A. (2023) · Journal of Alzheimer's Disease · doi:10.3233/jad-220800 · Cited by 39 · cited 1×
“602 Additionally, the upregulation of shared pathogenic kinases in COVID-19 and AD, such as epidermal growth factor receptors, vascular growth factor receptors, Bruton tyrosine kinase, spleen tyrosine kinase, c-ABL, and JAK/STAT, suggests potential interactions between immunological and…”
BackgroundJun, J., Yang, S., Lee, J.-H., Moon, H., Kim, J., Jung, H., Im, D., Oh, Y., Jang, M., Cho, H., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114894 · Cited by 38 · cited 1×
“519 Recently studied compounds 43 and 44 exhibited excellent performance in three behavioral tests of homozygous APPswe/PS1dE9 double transgenic mouse models and 3xTg mouse dementia models (Fig.”
BackgroundChen, L., Cruz, E., Oikari, L. E., Padmanabhan, P., Song, J. H., & Götz, J. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114517 · Cited by 38
Self-citationStanca, S., Rossetti, M., & Bongioanni, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813880 · Cited by 38
Metabotropic glutamate receptors: the potential for therapeutic applications in Alzheimer's disease
Caraci, F., Nicoletti, F., & Copani, A. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.12.001 · Cited by 37 · cited 1×
“207 Glutamate mainly interacts with NMDA receptors to control the in fl ux of sodium and calcium to neurons.”
BackgroundGSK-3β Allosteric Inhibition: A Dead End or a New Pharmacological Frontier?
Balboni, B., Masi, M., Rocchia, W., Girotto, S., & Cavalli, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087541 · Cited by 37
Can Infections Cause Alzheimer Disease?
Komaroff, A. L. (2020) · JAMA · doi:10.1001/jama.2020.4085 · Cited by 36
Ding, X.-W., Li, R., Geetha, T., Tao, Y.-X., & Babu, J. R. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165858 · Cited by 36 · cited 1×
“346,347 Downregulation of BDNF expression leads to weakened BDNF signaling in AD.”
BackgroundJiang, Y., Uhm, H., Ip, F. C., Ouyang, L., Lo, R. M. N., Cheng, E. Y. L., Cao, X., Tan, C. M. C., Law, B. C. H., Ortiz‐Romero, P., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13676 · Cited by 36 · cited 1×
“The use of “ composite biomarker panel ” 390 (effective combination of biomarkers) could comprehensively re fl ect the biological state of AD and enhance diagnostic accuracy.”
MethodDe Strooper, B., & Karran, E. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00057-w · Cited by 36
Rapid in silico Design of Potential Cyclic Peptide Binders Targeting Protein-Protein Interfaces
Santini, B. L., & Zacharias, M. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.573259 · Cited by 35 · cited 1×
“Although large and fl at PPI interfaces may be more conducive to peptide and protein drug targeting, 75,583,584 small molecule inhibitors also play a role in some AD-related PPIs due to their unique advantages.”
BackgroundAlthafar, Z. M. (2022) · Molecules · doi:10.3390/molecules27134124 · Cited by 35 · cited 1×
“180 Meanwhile, APOE4 could modify the behavior and function of activated microglia, contributing to increased A β deposition, tau-associated neurodegeneration, enhanced in fl am-mation, altered immune responses, and disrupted synaptic homeostasis.”
BackgroundDual Inhibitors of AChE and BACE-1 for Reducing Aβ in Alzheimer’s Disease: From In Silico to In Vivo
Stern, N., Gacs, A., Tátrai, E., Flachner, B., Hajdú, I., Dobi, K., Bágyi, I., Dormán, G., Lőrincz, Z., Cseh, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113098 · Cited by 35
Microglial autophagy in Alzheimer’s disease and Parkinson’s disease
Wang, Z., Wang, Q., Li, S., Li, X.-J., Yang, W., & He, D. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1065183 · Cited by 35 · cited 1×
“There is a growing emphasis on the involvement of chaperone-mediated autophagy, 232 contributions of glial cell autophagy, 233,234 and the precise causes of mitochondrial autophagy disorders.”
BackgroundKunkle, B., Grenier-Boley, B., Sims, R., Bis, J., Naj, A., Boland, A., Vronskaya, M., van der Lee, S., Amlie-Wolf, A., Bellenguez, C., et al. (2018) · doi:10.1101/294629 · Cited by 35
Wu, Z., Chen, C., Kang, S. S., Liu, X., Gu, X., Yu, S. P., Keene, C. D., Cheng, L., & Ye, K. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2100986118 · Cited by 34
Plasma ATN(I) classification and precision pharmacology in Alzheimer's disease
Imbimbo, B. P., Watling, M., Imbimbo, C., & Nisticò, R. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13084 · Cited by 34
Wang, Y., Sun, Y., Wang, Y., Jia, S., Qiao, Y., Zhou, Z., Shao, W., Zhang, X., Guo, J., Zhang, B., et al. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01324-4 · Cited by 34
Machine learning in Alzheimer’s disease drug discovery and target identification
Geng, C., Wang, Z., & Tang, Y. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102172 · Cited by 34
First Donepezil Transdermal Patch Approved for Alzheimer Disease
Larkin, H. D. (2022) · JAMA · doi:10.1001/jama.2022.6662 · Cited by 34
Dahlström, M., Madjid, N., Nordvall, G., Halldin, M. M., Vazquez-Juarez, E., Lindskog, M., Sandin, J., Winblad, B., Eriksdotter, M., & Forsell, P. (2021) · Cells · doi:10.3390/cells10081871 · Cited by 33
Georgakopoulos, N., Talapatra, S., Dikovskaya, D., Dayalan Naidu, S., Higgins, M., Gatliff, J., Ayhan, A., Nikoloudaki, R., Schaap, M., Valko, K., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00457 · Cited by 33 · cited 1×
“592 In summary, inhibition or activation of fundamental pathological interactions presents an alternative therapeutic avenue for AD.”
BackgroundNavigating the dementia landscape: Biomarkers and emerging therapies
Maheshwari, S., Singh, A., Ansari, V. A., Mahmood, T., Wasim, R., Akhtar, J., & Verma, A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102193 · Cited by 33
Cotrina, E. Y., Santos, L. M., Rivas, J., Blasi, D., Leite, J. P., Liz, M. A., Busquets, M. A., Planas, A., Prohens, R., Gimeno, A., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113847 · Cited by 32
Marde, V. S., Atkare, U. A., Gawali, S. V., Tiwari, P. L., Badole, S. P., Wankhede, N. L., Taksande, B. G., Upaganlawar, A., Umekar, M. J., & Kale, M. B. (2021) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2021.102961 · Cited by 32
Regulatory decisions diverge over aducanumab for Alzheimer’s disease
Lythgoe, M. P., Jenei, K., & Prasad, V. (2022) · BMJ · doi:10.1136/bmj-2021-069780 · Cited by 32
Progress Update: Fluid and Imaging Biomarkers in Alzheimer’s Disease
Sutphen, C. L., Fagan, A. M., & Holtzman, D. M. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.07.031 · Cited by 31
Deepen into sleep and wake patterns across Alzheimer's disease phenotypes
Falgàs, N., Walsh, C. M., Neylan, T. C., & Grinberg, L. T. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12304 · Cited by 31
Balancing cholesterol in the brain: from synthesis to disposal
Qian, L., Chai, A. B., Gelissen, I. C., & Brown, A. J. (2022) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2022.00015 · Cited by 31
The long road to a cure for Alzheimer’s disease is paved with failures
Moutinho, S. (2022) · Nature Medicine · doi:10.1038/s41591-022-02062-0 · Cited by 31 · cited 1×
“482,483 Biomarkers play a crucial role in patient selection, biological effect detection, dose optimization, and monitoring response progress, with recent approvals of A β monoclonal antibodies bene fi ting from new and accurate biomarkers.”
BackgroundSide effects loom over Alzheimer’s drugs
Couzin-Frankel, J. (2023) · Science · doi:10.1126/science.adk0830 · Cited by 31
Semagacestat for Treatment of Alzheimer's Disease
(2013) · New England Journal of Medicine · doi:10.1056/nejmc1310845 · Cited by 30
Jarrott, B. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.033 · Cited by 30 · cited 6×
“507,512 Compound 38 , incorporating cap group of melatonin and ferulic acid, enhanced HDAC6 selectivity while providing signi fi cant antioxidant capacity, alleviating spatial working and non-spatial long-term memory de fi cits in A β 25-35 -injected mice at lower doses.”
BackgroundInfluentialAccelerating Alzheimer's disease drug innovations from the research pipeline to patients
Goldman, D. P., Fillit, H., & Neumann, P. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.007 · Cited by 30 · cited 1×
“482,483 Biomarkers play a crucial role in patient selection, biological effect detection, dose optimization, and monitoring response progress, with recent approvals of A β monoclonal antibodies bene fi ting from new and accurate biomarkers.”
BackgroundProtein-Protein Interactions and Aggregation Inhibitors in Alzheimer’s Disease
Ganeshpurkar, A., Swetha, R., Kumar, D., Gangaram, G. P., Singh, R., Gutti, G., Jana, S., Kumar, D., Kumar, A., & Singh, S. K. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190304153353 · Cited by 30 · cited 1×
“75,579 582 Thus, disrupting these interactions may block some critical signaling pathways and potentially mitigate the pathological process of AD.”
BackgroundSinha, N., Karche, N. P., Verma, M. K., Walunj, S. S., Nigade, P. B., Jana, G., Kurhade, S. P., Hajare, A. K., Tilekar, A. R., Jadhav, G. R., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01569 · Cited by 30
Rubin, L., Ingram, L. A., Resciniti, N. V., Ashford‐Carroll, B., Leith, K. H., Rose, A., Ureña, S., McCollum, Q., & Friedman, D. B. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.784958 · Cited by 30
Ma, G., Zhang, D.-F., Zou, Q.-C., Xie, X., Xu, L., Feng, X.-L., Li, X., Han, J.-B., Yu, D., Deng, Z.-H., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00458-3 · Cited by 30
Some evolutionary perspectives on Alzheimer's disease pathogenesis and pathology
Glass, D. J., & Arnold, S. E. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2408 · Cited by 29
Kurimoto, E., Matsuda, S., Shimizu, Y., Sako, Y., Mandai, T., Sugimoto, T., Sakamoto, H., & Kimura, H. (2018) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.243774 · Cited by 29
Miao, S., He, Q., Li, C., Wu, Y., Liu, M., Chen, Y., Qi, S., & Gong, K. (2022) · Pharmaceutical Biology · doi:10.1080/13880209.2022.2102657 · Cited by 29 · cited 1×
“526 527 – 529 The dual inhibitor of AChE and BuChE, compound 45 , signi fi cantly enhanced the learning and memory abilities of aged AD mice.”
BackgroundIs It the Twilight of BACE1 Inhibitors?
Hrabinova, M., Pejchal, J., Kucera, T., Jun, D., Schmidt, M., & Soukup, O. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200503023323 · Cited by 28
Ghiboub, M., Elfiky, A. M. I., de Winther, M. P. J., Harker, N. R., Tough, D. F., & de Jonge, W. J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050336 · Cited by 28
Masitinib for the Treatment of Alzheimer’s Disease
Ettcheto, M., Cano, A., Sanchez-López, E., Verdaguer, E., Folch, J., Auladell, C., & Camins, A. (2021) · Neurodegenerative Disease Management · doi:10.2217/nmt-2021-0019 · Cited by 28
Alzheimer's disease: expedition into the unknown
Lancet, T. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32457-6 · Cited by 28
Liu, J., Liu, L., Zheng, L., Feng, K.-W., Wang, H.-T., Xu, J.-P., & Zhou, Z.-Z. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114503 · Cited by 28
Modulation of L-type calcium channels in Alzheimer’s disease: A potential therapeutic target
Crossley, C. A., Rajani, V., & Yuan, Q. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.11.049 · Cited by 28 · cited 1×
“319 Studies have shown that using L-type calcium channel blockers could mitigate the upregulation of L-type VGCCs and abnormal calcium in fl ux induced by A β .”
BackgroundYeo-Teh, N. S. L., & Tang, B. L. (2023) · Science and Engineering Ethics · doi:10.1007/s11948-022-00422-0 · Cited by 28
Dong, Y., Lu, J., Zhang, S., Chen, L., Wen, J., Wang, F., Mao, Y., Li, L., Zhang, J., Liao, S., et al. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106446 · Cited by 28
Self-citationWeston, P. S. J., Coath, W., Harris, M., Malone, I. B., Dickson, J. C., Aigbirhio, F. I., Cash, D. M., Zhang, H. G., & Schott, J. M. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13011 · Cited by 28 · cited 1×
“169 Despite initial investigations into drugs based on the tau hypothesis not yielding promising results, 152 numerous treatments are still actively being developed.”
BackgroundHigh mitochondrial calcium levels precede neuronal death in vivo in Alzheimer’s disease
Calvo-Rodriguez, M., & Bacskai, B. J. (2020) · Cell Stress · doi:10.15698/cst2020.07.226 · Cited by 27 · cited 1×
“293,294 This leads to mitochondrial calcium overload, causing cyclophilin D (CypD) to relocate from the mitochondrial matrix to the inner membrane, promoting the formation of the mitochondrial permeability transition pore (mPTP), further inhibiting ATP synthesis, activating oxidative stress, and…”
BackgroundCho, H., & Hah, J.-M. (2021) · Biomedicines · doi:10.3390/biomedicines9101431 · Cited by 27 · cited 1×
“516 Hah et al. have conducted in-depth studies on this target, continuously re fi ning and developing several generations of compounds based on the structure of pan-JNK inhibitor 42 , which was identi fi ed through an in-house kinase-focused library screening.”
BackgroundComorbidities confound Alzheimer’s blood tests
Schindler, S. E., & Karikari, T. K. (2022) · Nature Medicine · doi:10.1038/s41591-022-01875-3 · Cited by 27
D'Acunto, C. W., Kaplánek, R., Gbelcová, H., Kejík, Z., Bříza, T., Vasina, L., Havlík, M., Ruml, T., & Král, V. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.084 · Cited by 26 · cited 3×
“206 Speci fi cally, iron-induced oxidative stress causes increased release of iron from iron-containing proteins, converting Fe 3 + to Fe 2 + intracellularly.”
BackgroundInfluentialKumar, A., Nemeroff, C. B., Cooper, J. J., Widge, A. S., Rodríguez, C. I., Carpenter, L. L., & McDonald, W. M. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.19080873 · Cited by 26
Cao, Y., Yu, F., Lyu, Y., & Lu, X. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.1034243 · Cited by 26
Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site
Rippin, I., Khazanov, N., Ben Joseph, S., Kudinov, T., Berent, E., Arciniegas Ruiz, S. M., Marciano, D., Levy, L., Gruzman, A., Senderowitz, H., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228709 · Cited by 25 · cited 1×
“493,494 For example, compound 34 demonstrated these bene fi ts. 495 As the role of GSK-3 α in promoting A β production and tau phosphorylation in AD models is recognized, selective inhibition of GSK-3 α has emerged as a promising therapeutic strategy.”
BackgroundCSF Biomarkers of Alzheimer Disease in Patients With Concomitant α-Synuclein Pathology
Cousins, K. A. Q., Arezoumandan, S., Shellikeri, S., Ohm, D., Shaw, L. M., Grossman, M., Wolk, D., McMillan, C. T., Chen-Plotkin, A., Lee, E., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201202 · Cited by 25 · cited 1×
“393 For example, coexisting α Syn pathology in AD correlates with lower CSF P-tau181 and NG levels, 394 while comorbidity like hypertension lowers plasma A β concentration but increases plasma P-tau181 and P-tau217 levels.”
BackgroundHSV-1 cellular model reveals links between aggresome formation and early step of Alzheimer’s disease
Albaret, M. A., Textoris, J., Dalzon, B., Lambert, J., Linard, M., Helmer, C., Hacot, S., Ghayad, S. E., Ferréol, M., Mertani, H. C., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02376-8 · Cited by 25
Semagacestat's fall: where next for AD therapies?
(2013) · Nature Medicine · doi:10.1038/nm.3365 · Cited by 24
Tariot, P. N., Braeckman, R., & Oh, C. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-220530 · Cited by 24
Zhang, Q.-Q., Zhang, W.-J., & Chang, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1168848 · Cited by 24
Allosteric Modalities for Membrane-Bound Receptors: Insights from Drug Hunting for Brain Diseases
Coughlin, Q., Hopper, A. T., Blanco, M.-J., Tirunagaru, V. G., Robichaud, A. J., & Doller, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01651 · Cited by 23
Wang, X.-X., Xie, F., Jia, C.-C., Yan, N., Zeng, Y.-L., Wu, J.-D., & Liu, Z.-P. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113821 · Cited by 23
Huang, R., Zhu, Z., Wu, Q., Bekhit, A. E.-D. A., Wu, S., Chen, M., Wang, J., & Ding, Y. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1975093 · Cited by 23
Self-citationAβ-binding with alcohol dehydrogenase drives Alzheimer's disease pathogenesis: A review
Ye, Z., Liu, Y., Jin, X., Wu, Y., Zhao, H., Gao, T., Deng, Q., Cheng, J., Lin, J., & Tong, Z. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130580 · Cited by 23
Dallagnol, J. C. C., Khajehali, E., van der Westhuizen, E. T., Jörg, M., Valant, C., Gonçalves, A. G., Capuano, B., Christopoulos, A., & Scammells, P. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01812 · Cited by 22
What have we learnt from past failures in Alzheimer’s disease drug discovery?
Cacabelos, R. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2033724 · Cited by 22
Scrutinizing the Therapeutic Potential of PROTACs in the Management of Alzheimer’s Disease
Bhatia, S., Singh, M., Singh, T., & Singh, V. (2023) · Neurochemical Research · doi:10.1007/s11064-022-03722-w · Cited by 22 · cited 3×
“574 The PROTACs exploit the UPS system to precisely target speci fi c proteins, improving the accuracy and speed of protein degradation.”
BackgroundMethod
Research works printed but not linked: 3
- Cline, E. N., Bicca, M. A., Viola, K. L. & Klein, W. L. The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade. J. Alzheimers Dis. 64, S567–S610 (2018). 29843241 10.3233/JAD-179941 PMC6004937 · DOI · Paper page
- Cescon, E. et al. Scaffold Repurposing of in-House Chemical Library toward the Identification of New Casein Kinase 1 δ Inhibitors. ACS Med. Chem. Lett. 11, 1168–1174 (2020). 32550997 10.1021/acsmedchemlett.0c00028 PMC7294733 · DOI · Paper page
- Zhang, Y. et al. Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future. Signal Transduct. Target Ther. 8, 248 (2023). 37386015 10.1038/s41392-023-01484-7 PMC10310781 · DOI · Paper page
Cited by
NLRP3 inflammasome in neuroinflammation and central nervous system diseases
Xu, W., Huang, Y., & Zhou, R. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01275-w · Cited by 295
“Continuously activated microglia may cause persistent in fl ammation, leading to neuronal damage and promoting the formation of amyloid beta (A β ) plaques [43, 44].”
Exosome-powered neuropharmaceutics: unlocking the blood-brain barrier for next-gen therapies
Mehdizadeh, S., Mamaghani, M., Hassanikia, S., Pilehvar‐Soltanahmadi, Y., & Ertaş, Y. N. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03352-8 · Cited by 150
“Traditional drug therapies, such as cholinester-ase inhibitors and N-methyl D-aspartate (NMDA) receptor antagonists, often provide symptomatic relief rather than addressing the underlying pathology, and their efficacy is limited by their inability to cross the BBB efficiently [120].”
Chen, C., Wang, G., Li, D., & Zhang, F. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00307-1 · Cited by 148
Targeting Cytokine-Mediated Inflammation in Brain Disorders: Developing New Treatment Strategies
Mallick, R., Basak, S., Chowdhury, P., Bhowmik, P., Das, R. K., Banerjee, A., Paul, S., Pathak, S., & Duttaroy, A. K. (2025) · Pharmaceuticals · doi:10.3390/ph18010104 · Cited by 122
“Solanezumab, an anti-amyloid monoclonal antibody that does not directly target cytokines, has shown promise in decreasing levels of neuroinflammatory indicators in CSF [173,174].”
Ren, F., Wei, J., Chen, Q., Hu, M., Yu, L., Mi, J., Zhou, X., Qin, D., Wu, J., & Wu, A. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.030 · Cited by 97
Metadata
- Authors
- Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L.
- Affiliations
- Sichuan University (CN)
- University of Tennessee Health Science Center (US)
- Corresponding author
- Chen, Lei
- ORCID
- Wang, Jiaxing
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-08-23
- Volume
- 9
- Issue
- 1
- Pages
- 211-211
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC11344989
- OpenAlex
- W4401806028
- Semantic Scholar
- 8ff7d224cd5f81cb22fca07098d6f0ed92abd2bf
- Cited by
- 1,138
- References
- 674
- Citations by year
- 2026: 516 · 2025: 588 · 2024: 32
- FWCI
- 335.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Phosphodiesterase function and regulation
- Keywords
- Alzheimer's disease, Alzheimer's disease pathogenesis, amyloid hypothesis, tau protein, cholinergic hypothesis, neuroinflammation, oxidative stress, microbiota-gut-brain axis
- MeSH terms
- Drug Development, Alzheimer Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.